February 15, 2018 M&A, Partnerships

Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer

Basel, 15 February 2018 Roche to acquire Flatiron Health to accelerate industry-wide development and delivery of breakthrough medicines for patients with cancer Acquisition will bring together two companies committed to improving the lives of cancer patients through the evolving field of healthcare data and analytics The companies will leverage their combined expertise to advance the... Read more

February 14, 2018 Acad, Gov/Utilities

FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris

Basel, 14 February 2018 FDA grants priority review for Roche’s MabThera/ Rituxan (rituximab) for pemphigus vulgaris Pemphigus vulgaris (PV) is a life-threatening, autoimmune condition with limited treatment options1 The FDA previously granted Breakthrough Therapy Designation and Orphan Drug Designation for MabThera/Rituxan in PV Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food... Read more

February 12, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema

Basel, 12 February 2018 Phase II data support potential for Roche’s novel anti-VEGF/anti-angiopoietin-2 bispecific antibody, RG7716, for people with diabetic macular edema RG7716 is the first bispecific antibody designed specifically for the treatment of retinal eye diseases RG7716 demonstrated clinically meaningful and statistically significant improvements in visual acuity Key secondary and exploratory anatomical outcomes were... Read more

February 8, 2018 M&A, Partnerships

Roche purchases shares in tender offer for Ignyta, Inc.

Basel, 08 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common... Read more

February 8, 2018 M&A, Partnerships

Roche purchases shares in tender offer for Ignyta, Inc.

Basel, 08 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common... Read more

February 8, 2018 M&A, Partnerships

Roche purchases shares in tender offer for Ignyta, Inc.

Basel, 08 February 2018 Roche purchases shares in tender offer for Ignyta, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common... Read more

February 6, 2018 Licensing, IP, and Legal

Reminder: Invitation to Roche's Virtual Pipeline Event

Basel, 06 February 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody RG7716 in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event... Read more

February 6, 2018 Licensing, IP, and Legal

Reminder: Invitation to Roche's Virtual Pipeline Event

Basel, 06 February 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event Phase 2 results of the bispecific VEGF/Ang2 antibody RG7716 in diabetic macula edema presented at Angiogenesis 2018 We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Tuesday, 13 February 2018. This is the first event... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more

February 6, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer

Basel, 06 February 2018 Phase III IMmotion151 study showed Roche’s TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer TECENTRIQ and Avastin met co-primary endpoint of improvement in investigator-assessed progression-free survival (PFS) compared with sunitinib for people whose disease expressed PD-L1... Read more